IKENA ONCOLOGY INC. - COMMON STOCK

Ikena Oncology and Vall d’Hebron Institute of Oncology Announce Research & Development Collaboration

02 May 2022 07:00:00 By Nasdaq GlobeNewswire

Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

28 Apr 2022 07:00:02 By Nasdaq GlobeNewswire

Ikena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate Development

13 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

17 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting

07 Mar 2022 16:30:00 By Nasdaq GlobeNewswire

Ikena Oncology to Participate in Cowen 42nd Annual Health Care Conference

01 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Ikena Appoints Richard Wooster, Ph.D., to its Board of Directors

26 Jan 2022 07:00:00 By Nasdaq GlobeNewswire

Ikena Appoints Michelle Zhang, Ph.D., Industry and Company Veteran, as Chief Scientific Officer

08 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Ikena Oncology Presents Data at SITC 36th Annual Meeting Describing the Indication Selection Methodology, Translational Data, and Trial in Progress for IK-175

12 Nov 2021 07:00:03 By Nasdaq GlobeNewswire

Ikena Oncology Reports Third Quarter 2021 Financial Results and Corporate Update

10 Nov 2021 07:00:02 By Nasdaq GlobeNewswire

Ikena Oncology to Participate in November 2021 Virtual Investor Conferences

04 Nov 2021 07:00:02 By Nasdaq GlobeNewswire

Ikena Oncology Announces FDA Acceptance of IND Application of Novel TEAD Inhibitor IK-930

02 Nov 2021 08:00:02 By Nasdaq GlobeNewswire

Ikena Oncology Presents Data at AACR-NCI-EORTC Virtual Conference Demonstrating Potential of TEAD Inhibitors in Cancer Treatment

07 Oct 2021 09:00:00 By Nasdaq GlobeNewswire

Ikena Oncology to Present a Trial-in-Progress Update, Translational Data, and Indication Selection Methodology for Novel AHR Inhibition Program at the 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

01 Oct 2021 08:15:00 By Nasdaq GlobeNewswire

Ikena Oncology to Participate in September 2021 Virtual Investor Conferences

02 Sep 2021 07:00:02 By Nasdaq GlobeNewswire

Ikena Oncology Reports Second Quarter 2021 Financial Results and Provides Update on Key Programs

12 Aug 2021 07:00:02 By Nasdaq GlobeNewswire

Ikena Oncology to Participate in Targeted Oncology Panel at the William Blair Biotech Focus Conference 2021

08 Jul 2021 07:00:00 By Nasdaq GlobeNewswire